All In Biotech

Free tool

FAERS Monitor: Xenon Xe 133

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018327 or its brand name (Xenon Xe 133, Xenon Xe-133). Reports on generic versions are filed under their own applications.

Reports

13

Serious

2

15% of reports

Hospitalization

1

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • occupational exposure to product4
  • nasal discomfort2
  • throat irritation2
  • urticaria2
  • accidental exposure1
  • accidental exposure to product1
  • alanine aminotransferase decreased1
  • beta 2 microglobulin increased1
  • blood alkaline phosphatase increased1
  • blood bilirubin decreased1
  • blood cholinesterase decreased1
  • blood creatine phosphokinase decreased1
  • blood phosphorus increased1
  • blood potassium decreased1
  • cardiac failure1

Reports by year received

View as table
YearReports
20091
20162
20182
20192
20201
20245

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
beta 2 microglobulin increased16229.0943.81,550
blood cholinesterase decreased15932.4899.11,477
blood creatine phosphokinase decreased14952.8751.11,233
blood bilirubin decreased12624.9398.6654
alanine aminotransferase decreased12240.0340.3558
occupational exposure to productSignal41007.3445.53,077
blood phosphorus increased1592.890.1147
nasal discomfort2408.3114.1456
accidental exposure1388.759.196
throat irritation272.120.278
blood alkaline phosphatase increased165.29.915
blood potassium decreased153.88.212
cardiac failure120.23.14
urticaria219.35.419
accidental exposure to product115.72.43

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.